Premium
Cytogenetics of extramedullary manifestations in multiple myeloma
Author(s) -
Billecke Lisa,
Murga Penas Eva M.,
May Annette M.,
Engelhardt Monika,
Nagler Ar,
Leiba Merav,
Schiby Ginette,
Kröger Nicolaus,
Zustin Jozef,
Marx Andreas,
Matschke Jakob,
Tiemann Markus,
Goekkurt Eray,
Heidtmann HansHeinrich,
Vettorazzi Eik,
Dierlamm Judith,
Bokemeyer Carsten,
Schilling Georgia
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12223
Subject(s) - multiple myeloma , fluorescence in situ hybridization , pathology , medicine , bone marrow , cytogenetics , immunophenotyping , plasmacytoma , plasma cell neoplasm , plasma cell , immunohistochemistry , biology , immunology , antigen , chromosome , biochemistry , gene
Summary Extramedullary disease in patients with multiple myeloma is a rare event, occurring mostly in advanced disease or relapse. Outcome is poor and prognostic factors predicting the development of extramedullary disease have not been defined. We investigated cytogenetic alterations of myeloma cells in different extramedullary manifestations by adapting the fluorescence in situ hybridization ( FISH ) technique in combination with cytoplasmic immunoglobulin staining to study the cytogenetics of plasma cell tumours on paraffin embedded material. Thirty six patients were investigated: 19 with extramedullary disease, 11 with skeletal extramedullary disease and six with solitary extramedullary plasmacytoma. The first two groups showed the following results: del(17p13) 32% vs. 27%, del(13q14) 35% vs. 27%, MYC ‐overrepresentation 28% vs. 18% and t(4;14) 37% vs. 18%. We detected an overall higher incidence of del(17p13) in both groups compared to data from bone marrow samples of multiple myeloma reported to date (range 7–16%). The solitary extramedullary plasmacytomas presented overall less cytogenetic aberrations than the other groups. Most important, three patients with extramedullary disease and one with skeletal extramedullary disease presented different FISH findings in the extramedullary tumour compared to their bone marrow plasma cells. del(17p13), occurring additional in three of four cases, seems a strong marker for extramedullary progression of myeloma.